Tyra Biosciences Strengthens Leadership with Appointment of Bhavesh Ashar as COO and Heather Faulds as CRO
Tyra Biosciences, a clinical-stage biotechnology company focusing on precision medicines targeting FGFR biology, appointed Bhavesh Ashar as Chief Operating Officer (COO) effective immediately in late 2025.
Heather Faulds was appointed Chief Regulatory Officer (CRO), joining the company on December 8, 2025.
Bhavesh Ashar brings over 25 years of experience in biopharmaceuticals with a strong background in oncology commercialization, including prior roles at SpringWorks Therapeutics, Bayer, and Sanofi Genzyme.
Ashar's expertise is expected to advance Tyra's operational efficiency and strategic growth during critical development phases.
Heather Faulds has over 20 years of global regulatory strategy experience, previously serving as Senior Vice President of Global Regulatory Sciences at Blueprint Medicines, playing key roles in approvals for therapies like SPINRAZA and LYBALVI.
Faulds’s regulatory expertise will support Tyra in managing clinical development and regulatory pathways essential for bringing innovative therapies to market.
Tyra Biosciences focuses on developing next-generation precision medicines, with its lead candidate dabogratinib targeting FGFR3 and multiple clinical-stage programs in oncology and genetically defined conditions.
The appointments demonstrate Tyra’s commitment to strengthening leadership and advancing its pipeline to deliver transformative treatments for oncology and rare diseases.